A Phase 2 interventional study of SYL1801 in Wet Macular Degeneration, Neovascular Age-related Macular Degeneration and Macular Degeneration, sponsored by Sylentis, S.A.. Completed at 16 sites in 3 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
This study's enrollment of 99 is close to the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Browse Wet Macular Degeneration studies →Sylentis, S.A. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
42 treatment days
Drug: SYL1801
42 treatment days
Drug: SYL1801
42 treatment days
Drug: SYL1801
1 drop in the eligible eye
Change from Baseline on visual acuity on Day 42 after last instillation of the assigned dose level
ETDRS chart
Time frame: 42 days after first administration
Proportion of subjects within each cohort who maintained visual acuity on Day 42 after last instillation of the assigned dose level
ETDRS chart
Time frame: 42 days after first administration
Proportion of subjects within each cohort who gained visual acuity on Day 42 after last instillation of the assigned dose level
ETDRS chart
Time frame: Through study completion, up to 42 days
Proportion of subjects within each cohort who needed rescue medication at any point of the study
Time frame: Through study completion, up to 42 days
Change from Baseline on flow area on Day 42 after last instillation of the assigned
Optical Coherence Tomography Angiography (OCTA)
Time frame: 42 days after first administration
Change from Screening on leakage area on Day 42 after last instillation of the assigned
Fluorescein Angiography
Time frame: 43 days after first administration
Change from Baseline on intraocular pressure (IOP)
Tonometry
Time frame: 42 days after first administration
Adverse Event Evaluation
Time frame: Through study completion, up to 42 days
Ran from Nov 2022 to primary completion in Dec 2024, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.